Trade BioCryst - BCRX CFD

Add to favourite

4.41

1.56%

0.05

Low: 4.26

High: 4.53

Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.05

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

BioCryst Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	4.48
Open*	4.52
1-Year Change*	-39.49%
Day's Range*	4.26 - 4.53
52 wk Range	4.83-11.11
Average Volume (10 days)	4.49M
Average Volume (3 months)	81.71M
Market Cap	1.18B
P/E Ratio	-100.00K
Shares Outstanding	204.81M
Revenue	317.56M
EPS	-1.25
Dividend (Yield %)	N/A
Beta	1.92
Next Earnings Date	Feb 19, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	4.48	-0.10	-2.18%	4.58	4.68	4.47
Apr 17, 2024	4.56	-0.07	-1.51%	4.63	4.76	4.55
Apr 16, 2024	4.59	0.00	0.00%	4.59	4.69	4.52
Apr 15, 2024	4.65	-0.07	-1.48%	4.72	4.76	4.57
Apr 12, 2024	4.75	-0.33	-6.50%	5.08	5.13	4.68
Apr 11, 2024	5.08	0.16	3.25%	4.92	5.09	4.80
Apr 10, 2024	4.85	0.21	4.53%	4.64	4.88	4.54
Apr 9, 2024	4.78	0.18	3.91%	4.60	4.85	4.59
Apr 8, 2024	4.58	-0.03	-0.65%	4.61	4.64	4.52
Apr 5, 2024	4.58	0.07	1.55%	4.51	4.63	4.44
Apr 4, 2024	4.57	-0.19	-3.99%	4.76	4.81	4.56
Apr 3, 2024	4.71	0.08	1.73%	4.63	4.74	4.57
Apr 2, 2024	4.66	-0.26	-5.28%	4.92	4.98	4.66
Apr 1, 2024	5.03	0.01	0.20%	5.02	5.06	4.88
Mar 28, 2024	5.05	-0.13	-2.51%	5.18	5.31	5.05
Mar 27, 2024	5.12	0.06	1.19%	5.06	5.18	4.95
Mar 26, 2024	4.98	-0.02	-0.40%	5.00	5.12	4.97
Mar 25, 2024	4.89	-0.07	-1.41%	4.96	5.05	4.81
Mar 22, 2024	4.99	-0.46	-8.44%	5.45	5.45	4.99
Mar 21, 2024	5.46	-0.02	-0.36%	5.48	5.85	5.43

BioCryst Events

Time (UTC)	Country	Event
Wednesday, May 1, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 BioCryst Pharmaceuticals Inc Earnings Release Q1 2024 BioCryst Pharmaceuticals Inc Earnings Release Forecast - Previous -
Wednesday, June 12, 2024
Time (UTC) 14:00	Country US	Event BioCryst Pharmaceuticals Inc Annual Shareholders Meeting BioCryst Pharmaceuticals Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 BioCryst Pharmaceuticals Inc Earnings Release Q2 2024 BioCryst Pharmaceuticals Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	270.827	157.17	17.812	48.835	20.653
Revenue	270.827	157.17	17.812	48.835	20.653
Cost of Revenue, Total	6.594	7.264	1.676	4.101	0.471
Gross Profit	264.233	149.906	16.136	44.734	20.182
Total Operating Expense	419.262	279.052	194.58	148.29	114.873
Selling/General/Admin. Expenses, Total	159.371	118.818	67.929	37.121	13.614
Research & Development	253.297	208.808	122.964	107.068	84.888
Operating Income	-148.435	-121.882	-176.768	-99.455	-94.22
Interest Income (Expense), Net Non-Operating	-95.948	-59.927	-6.046	-9.442	-7.032
Net Income Before Taxes	-244.383	-181.809	-182.814	-108.897	-101.252
Net Income After Taxes	-247.116	-184.062	-182.814	-108.897	-101.252
Net Income Before Extra. Items	-247.116	-184.062	-182.814	-108.897	-101.252
Net Income	-247.116	-184.062	-182.814	-108.897	-101.252
Income Available to Common Excl. Extra. Items	-247.116	-184.062	-182.814	-108.897	-101.252
Income Available to Common Incl. Extra. Items	-247.116	-184.062	-182.814	-108.897	-101.252
Diluted Net Income	-247.116	-184.062	-182.814	-108.897	-101.252
Diluted Weighted Average Shares	185.908	179.117	167.267	115.6	103.185
Diluted EPS Excluding Extraordinary Items	-1.32924	-1.02761	-1.09295	-0.94202	-0.98127
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS	-1.32924	-1.23024	-1.08092	-0.94202	-0.82717
Total Extraordinary Items
Unusual Expense (Income)	0	-55.838	2.011		15.9

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	82.491	68.778	79.545	75.827	65.532
Revenue	82.491	68.778	79.545	75.827	65.532
Cost of Revenue, Total	0.95	0.938	2.496	3.613	0.247
Gross Profit	81.541	67.84	77.049	72.214	65.285
Total Operating Expense	132.213	97.193	125.856	93.272	100.254
Selling/General/Admin. Expenses, Total	50.997	47.867	50.153	36.919	38.017
Research & Development	51.247	48.388	73.207	52.74	61.99
Operating Income	-49.722	-28.415	-46.311	-17.445	-34.722
Interest Income (Expense), Net Non-Operating	-24.864	-24.247	-25.154	-23.553	-23.281
Net Income Before Taxes	-74.586	-52.662	-71.465	-40.998	-58.003
Net Income After Taxes	-75.326	-53.333	-71.541	-42.52	-58.859
Net Income Before Extra. Items	-75.326	-53.333	-71.541	-42.52	-58.859
Net Income	-75.326	-53.333	-71.541	-42.52	-58.859
Income Available to Common Excl. Extra. Items	-75.326	-53.333	-71.541	-42.52	-58.859
Income Available to Common Incl. Extra. Items	-75.326	-53.333	-71.541	-42.52	-58.859
Diluted Net Income	-75.326	-53.333	-71.541	-42.52	-58.859
Diluted Weighted Average Shares	189.118	188.509	186.934	186.18	185.605
Diluted EPS Excluding Extraordinary Items	-0.3983	-0.28292	-0.38271	-0.22838	-0.31712
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.29856	-0.28292	-0.38271	-0.22838	-0.31712
Unusual Expense (Income)	29.019		0

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	516.5	566.136	323.8	164.345	114.352
Cash and Short Term Investments	424.31	507.601	300.366	136.226	104.467
Cash & Equivalents	304.767	504.389	272.127	114.172	26.731
Short Term Investments	119.543	3.212	28.239	22.054	77.736
Total Receivables, Net	50.599	29.413	8.646	22.146	4.293
Accounts Receivable - Trade, Net	50.599	29.413	8.646	22.146	4.293
Total Inventory	27.533	15.791	7.039	0	1.649
Prepaid Expenses	12.586	9.986	5.528	4.422	2.39
Other Current Assets, Total	1.472	3.345	2.221	1.551	1.553
Total Assets	550	588.151	334.715	175.282	146.841
Property/Plant/Equipment, Total - Net	15.423	15.186	10.915	10.937	9.135
Property/Plant/Equipment, Total - Gross	29.322	25.925	20.892	18.911	15.23
Accumulated Depreciation, Total	-13.899	-10.739	-9.977	-7.974	-6.095
Long Term Investments	18.077	6.829		0	22.376
Other Long Term Assets, Total					0.978
Total Current Liabilities	105.514	103.718	105.654	92.335	69.477
Accounts Payable	14.356	27.808	18.713	13.988	7.769
Accrued Expenses	89.934	74.489	56.791	37.646	27.739
Notes Payable/Short Term Debt	0	0	30	29.561	29.121
Other Current Liabilities, Total	1.224	1.421	0.15	2.12	0.221
Total Liabilities	844.597	695.137	353.977	137.03	97.606
Total Long Term Debt	733.279	585.457	244.452	41.289	28.075
Long Term Debt	733.279	585.457	244.452	41.289	25.372
Capital Lease Obligations					2.703
Other Liabilities, Total	5.804	5.962	3.871	3.406	0.054
Total Equity	-294.597	-106.986	-19.262	38.252	49.235
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	1.879	1.843	1.769	1.541	1.101
Additional Paid-In Capital	1158.12	1098.5	1002.41	877.3	780.4
Retained Earnings (Accumulated Deficit)	-1454.62	-1207.5	-1023.44	-840.628	-731.969
Other Equity, Total	0.026	0.177	0.003	0.039	-0.297
Total Liabilities & Shareholders’ Equity	550	588.151	334.715	175.282	146.841
Total Common Shares Outstanding	187.906	184.35	176.883	154.082	110.063
Current Port. of LT Debt/Capital Leases			0	9.02	4.627

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	502.466	511.056	490.883	516.5	509.001
Cash and Short Term Investments	397.59	410.67	398.158	424.31	426.858
Cash & Equivalents	150.905	146.215	155.136	304.767	246.899
Short Term Investments	246.685	264.455	243.022	119.543	179.959
Total Receivables, Net	53.646	57.667	48.639	50.599	42.61
Accounts Receivable - Trade, Net	53.646	57.667	48.639	50.599	42.61
Total Inventory	29.63	27.033	27.466	27.533	27.019
Prepaid Expenses	20.016	14.112	15.157	12.586	11.07
Other Current Assets, Total	1.584	1.574	1.463	1.472	1.444
Total Assets	522.924	529.885	509.737	550	558.594
Property/Plant/Equipment, Total - Net	20.379	15.384	15.422	15.423	15.261
Property/Plant/Equipment, Total - Gross	17.73	12.397	11.924	11.155	10.671
Accumulated Depreciation, Total	-6.35	-5.451	-4.878	-4.349	-3.874
Total Current Liabilities	90.763	93.498	85.157	105.514	81.637
Accounts Payable	10.567	13.889	6.254	14.356	8.622
Accrued Expenses	79.674	77.83	77.703	89.934	71.461
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.522	1.779	1.2	1.224	1.554
Total Liabilities	933.91	918.598	838.024	844.597	801.253
Total Long Term Debt	833.181	819.297	746.933	733.279	713.648
Long Term Debt	833.181	819.297	746.933	733.279	713.648
Other Liabilities, Total	9.966	5.803	5.934	5.804	5.968
Total Equity	-410.986	-388.713	-328.287	-294.597	-242.659
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	1.898	1.895	1.889	1.879	1.864
Additional Paid-In Capital	1205.74	1191.98	1177.19	1158.12	1138.65
Retained Earnings (Accumulated Deficit)	-1619.43	-1583.28	-1507.95	-1454.62	-1383.08
Other Equity, Total	0.8	0.69	0.585	0.026	-0.098
Total Liabilities & Shareholders’ Equity	522.924	529.885	509.737	550	558.594
Total Common Shares Outstanding	189.803	189.491	188.883	187.906	186.411
Long Term Investments	0	3.445	3.432	18.077	34.332
Other Long Term Assets, Total	0.079

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-247.116	-184.062	-182.814	-108.897	-101.252
Cash From Operating Activities	-161.85	-142.157	-135.108	-89.584	-92.565
Cash From Operating Activities	1.437	0.777	0.748	0.724	0.77
Non-Cash Items	142.774	33.004	20.083	19.461	11.447
Changes in Working Capital	-58.945	8.124	26.875	-0.872	-3.53
Cash From Investing Activities	-128.238	15.804	-6.856	77.934	4.768
Capital Expenditures	-1.351	-2.385	-0.514	-0.343	-0.366
Other Investing Cash Flow Items, Total	-126.887	18.189	-6.342	78.277	5.134
Cash From Financing Activities	88.027	359.668	300.589	99.098	62.504
Issuance (Retirement) of Stock, Net	14.955	65.794	110.542	79.621	56.252
Issuance (Retirement) of Debt, Net	73.072	293.874	190.047	19.477	6.252
Net Change in Cash	-201.495	233.386	158.625	87.448	-25.293
Foreign Exchange Effects	0.566	0.071

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-53.333	-247.116	-175.575	-133.055	-74.196
Cash From Operating Activities	-47.512	-161.85	-138.001	-105.557	-77.8
Cash From Operating Activities	0.405	1.437	1.041	0.652	0.317
Non-Cash Items	33.074	142.774	83.72	56.105	28.634
Changes in Working Capital	-27.658	-58.945	-47.187	-29.259	-32.555
Cash From Investing Activities	-107.109	-128.238	-205.453	-135.91	-38.472
Capital Expenditures	-0.16	-1.351	-0.825	-0.65	-0.406
Other Investing Cash Flow Items, Total	-106.949	-126.887	-204.628	-135.26	-38.066
Cash From Financing Activities	5.077	88.027	83.828	7.503	7.356
Issuance (Retirement) of Stock, Net	5.077	14.955	10.756	7.503	7.356
Net Change in Cash	-149.64	-201.495	-259.391	-233.715	-108.876
Foreign Exchange Effects	-0.096	0.566	0.235	0.249	0.04
Issuance (Retirement) of Debt, Net		73.072	73.072

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BioCryst Company profile

BioCryst (BCRX) is a commercial-stage biotech firm that discovers novel, oral, small-molecule medicines.

The company focuses on oral treatments for rare diseases in which significant unmet medical needs exist. BioCryst’s drug portfolio consists of ORLADEYO for prevention of hereditary angioedema. ORLADEYO has been approved in the US, EU, UK, Japan and UAE. Other drugs like RAPIACTA, RAPIVAB and PERAMIFLU are approved in select geographies.

The company is developing an oral small molecule Factor D inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.

According to the company, its focus on rare diseases market helps it control costs effectively. BioCryst selects disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market.

BioCryst’s US headquarters is located in Durham, North Carolina while its European headquarters is in Dublin, Ireland. Jon P Stonehouse is the chief executive officer and William P Sheridan is the chief medical officer of BioCryst.

The company was founded in 1966. It completed its initial public offering (IPO) in March 1994 and is listed on the Nasdaq stock exchange under the ticker symbol BCRX. According to the company’s price history, BCRX stock price hit an all-time high of $37.25 on 1 March 2000.

You can follow the ups and downs of the BioCryst stock price at Capital.com. Always stay on top of the latest price developments with our live BCRX stock chart.

Industry:

Bio Therapeutic Drugs

4505 Emperor Blvd Ste 200
DURHAM
NORTH CAROLINA 27703-8457
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024